- Home
- CMA vs ROIV Comparison
CMA vs ROIV Comparison
Compare CMA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- ROIV
- Stock Information
- Founded
- CMA 1849
- ROIV 2014
- Country
- CMA United States
- ROIV United Kingdom
- Employees
- CMA N/A
- ROIV N/A
- Industry
- CMA Major Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CMA Finance
- ROIV Health Care
- Exchange
- CMA Nasdaq
- ROIV Nasdaq
- Market Cap
- CMA 7.7B
- ROIV 7.8B
- IPO Year
- CMA N/A
- ROIV N/A
- Fundamental
- Price
- CMA $61.23
- ROIV $11.36
- Analyst Decision
- CMA Hold
- ROIV Buy
- Analyst Count
- CMA 22
- ROIV 4
- Target Price
- CMA $61.57
- ROIV $17.50
- AVG Volume (30 Days)
- CMA 1.6M
- ROIV 7.8M
- Earning Date
- CMA 07-18-2025
- ROIV 08-07-2025
- Dividend Yield
- CMA 4.59%
- ROIV N/A
- EPS Growth
- CMA 4.95
- ROIV N/A
- EPS
- CMA 5.29
- ROIV N/A
- Revenue
- CMA $3,234,000,000.00
- ROIV $29,053,000.00
- Revenue This Year
- CMA $7.26
- ROIV $3.28
- Revenue Next Year
- CMA $2.83
- ROIV $156.84
- P/E Ratio
- CMA $11.70
- ROIV N/A
- Revenue Growth
- CMA N/A
- ROIV N/A
- 52 Week Low
- CMA $48.12
- ROIV $8.73
- 52 Week High
- CMA $73.45
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CMA 54.12
- ROIV 52.70
- Support Level
- CMA $62.38
- ROIV $10.71
- Resistance Level
- CMA $64.08
- ROIV $11.58
- Average True Range (ATR)
- CMA 1.30
- ROIV 0.31
- MACD
- CMA 0.14
- ROIV 0.02
- Stochastic Oscillator
- CMA 56.49
- ROIV 60.93
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.